{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:53Z","timestamp":1787032793244,"version":"build-2736575974"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"DOI":"10.7759\/cureus.110365","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:43:02Z","timestamp":1780767782000},"source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib in Biologic-Na\u00efve Patients With Acute Severe Ulcerative Colitis: A Case Report of a Promising Alternative Rescue Therapy"],"prefix":"10.7759","author":[{"given":"Sneh","family":"Parekh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Boustany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasasvhinie","family":"Santharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Aleman Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Lupianez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianny","family":"Sulbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2023.11.001","article-title":"Systematic review: outcome prediction in acute severe ulcerative colitis","volume":"3","author":"Angkeow J","year":"2024","unstructured":"Angkeow J, Rothman A, Chaaban L, Paul N, Melia J. Systematic review: outcome prediction in acute severe ulcerative colitis. Gastro Hep Adv. 2024, 3:260-70. 10.1016\/j.gastha.2023.11.001","journal-title":"Gastro Hep Adv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein JD","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020, 158:1450-61. 10.1053\/j.gastro.2020.01.006","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12442","article-title":"Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies","volume":"11","author":"Calm\u00e9jane L","year":"2023","unstructured":"Calm\u00e9jane L, Laharie D, Kirchgesner J, Uzzan M. Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies. United European Gastroenterol J. 2023, 11:722-32. 10.1002\/ueg2.12442","journal-title":"United European Gastroenterol J"},{"key":"ref4","unstructured":"RINVOQ\u00ae (upadacitinib) extended-release tablets, for oral use. (2025). Accessed. June 06, 2026: https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae191","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review","volume":"31","author":"Damianos JA","year":"2025","unstructured":"Damianos JA, Osikoya O, Brennan G. Upadacitinib for acute severe ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2025, 31:1145-9. 10.1093\/ibd\/izae191","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","volume":"119","author":"Berinstein JA","year":"2024","unstructured":"Berinstein JA, Karl T, Patel A, et al.. Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024, 119:1421-5. 10.14309\/ajg.0000000000002674","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin DT","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019, 114:384-413. 10.14309\/ajg.0000000000000152","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese S","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al.. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022, 399:2113-28. 10.1016\/S0140-6736(22)00581-5","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Colombel JF, Takeuchi K, et al.. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin Gastroenterol Hepatol. 2023, 21:2347-58.e6. 10.1016\/j.cgh.2022.11.029","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500078-upadacitinib-in-biologic-nave-patients-with-acute-severe-ulcerative-colitis-a-case-report-of-a-promising-alternative-rescue-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:43:07Z","timestamp":1780767787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500078-upadacitinib-in-biologic-nave-patients-with-acute-severe-ulcerative-colitis-a-case-report-of-a-promising-alternative-rescue-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.110365","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}